Pneumocystis jirovecii pneumonia following everolimus treatment of metastatic breast cancer

Pneumocystis jirovecii pneumonia following everolimus treatment of metastatic breast cancer

Everolimus is an inhibitor of mammalian target of rapamycin with anti-tumour activity. While everolimus is known to cause drug-induced pneumonitis, it is rarely associated with Pneumocystis jirovecii pneumonia (PJP). We report a patient on everolimus therapy for metastatic breast cancer that develop...

Full description

Bibliographic Details
Main Authors: Kelvin Teck-Hong Kuik, Jason Trubiano, Leon J. Worth, Nur-shirin Harun, Daniel Steinfort, Douglas Johnson
Format: Article
Language:English
Published: Elsevier 2014-10-01
Series:Medical Mycology Case Reports
Subjects:
PJP
Pneumocystis
Pneumonitis
Everolimus
Cancer
Online Access:http://www.sciencedirect.com/science/article/pii/S2211753914000414
id doaj-6119cdaf10474556877191702929e476
record_format Article
spelling doaj-6119cdaf10474556877191702929e4762020-11-25T03:49:52ZengElsevierMedical Mycology Case Reports2211-75392014-10-016C343610.1016/j.mmcr.2014.08.007Pneumocystis jirovecii pneumonia following everolimus treatment of metastatic breast cancerKelvin Teck-Hong Kuik0Jason Trubiano1Leon J. Worth2Nur-shirin Harun3Daniel Steinfort4Douglas Johnson5Department of General Medicine, Peter MacCallum Cancer Centre, East Melbourne, AustraliaDepartment of Infectious Diseases, Peter MacCallum Cancer Centre, East Melbourne, AustraliaDepartment of Infectious Diseases, Peter MacCallum Cancer Centre, East Melbourne, AustraliaDepartment of General Medicine, Peter MacCallum Cancer Centre, East Melbourne, AustraliaDepartment of General Medicine, Peter MacCallum Cancer Centre, East Melbourne, AustraliaDepartment of General Medicine, Peter MacCallum Cancer Centre, East Melbourne, AustraliaEverolimus is an inhibitor of mammalian target of rapamycin with anti-tumour activity. While everolimus is known to cause drug-induced pneumonitis, it is rarely associated with Pneumocystis jirovecii pneumonia (PJP). We report a patient on everolimus therapy for metastatic breast cancer that developed PJP. Diagnosis was based on clinical features and a quantitative polymerase chain reaction for P. jirovecii DNA. Clinicians should consider PJP as a potential cause of pulmonary infiltrates in patients treated with everolimus.http://www.sciencedirect.com/science/article/pii/S2211753914000414PJPPneumocystisPneumonitisEverolimusCancer
collection DOAJ
language English
format Article
sources DOAJ
author Kelvin Teck-Hong Kuik
Jason Trubiano
Leon J. Worth
Nur-shirin Harun
Daniel Steinfort
Douglas Johnson
spellingShingle Kelvin Teck-Hong Kuik
Jason Trubiano
Leon J. Worth
Nur-shirin Harun
Daniel Steinfort
Douglas Johnson
Pneumocystis jirovecii pneumonia following everolimus treatment of metastatic breast cancer
Medical Mycology Case Reports
PJP
Pneumocystis
Pneumonitis
Everolimus
Cancer
author_facet Kelvin Teck-Hong Kuik
Jason Trubiano
Leon J. Worth
Nur-shirin Harun
Daniel Steinfort
Douglas Johnson
author_sort Kelvin Teck-Hong Kuik
title Pneumocystis jirovecii pneumonia following everolimus treatment of metastatic breast cancer
title_short Pneumocystis jirovecii pneumonia following everolimus treatment of metastatic breast cancer
title_full Pneumocystis jirovecii pneumonia following everolimus treatment of metastatic breast cancer
title_fullStr Pneumocystis jirovecii pneumonia following everolimus treatment of metastatic breast cancer
title_full_unstemmed Pneumocystis jirovecii pneumonia following everolimus treatment of metastatic breast cancer
title_sort pneumocystis jirovecii pneumonia following everolimus treatment of metastatic breast cancer
publisher Elsevier
series Medical Mycology Case Reports
issn 2211-7539
publishDate 2014-10-01
description Everolimus is an inhibitor of mammalian target of rapamycin with anti-tumour activity. While everolimus is known to cause drug-induced pneumonitis, it is rarely associated with Pneumocystis jirovecii pneumonia (PJP). We report a patient on everolimus therapy for metastatic breast cancer that developed PJP. Diagnosis was based on clinical features and a quantitative polymerase chain reaction for P. jirovecii DNA. Clinicians should consider PJP as a potential cause of pulmonary infiltrates in patients treated with everolimus.
topic PJP
Pneumocystis
Pneumonitis
Everolimus
Cancer
url http://www.sciencedirect.com/science/article/pii/S2211753914000414
work_keys_str_mv AT kelvinteckhongkuik pneumocystisjiroveciipneumoniafollowingeverolimustreatmentofmetastaticbreastcancer
AT jasontrubiano pneumocystisjiroveciipneumoniafollowingeverolimustreatmentofmetastaticbreastcancer
AT leonjworth pneumocystisjiroveciipneumoniafollowingeverolimustreatmentofmetastaticbreastcancer
AT nurshirinharun pneumocystisjiroveciipneumoniafollowingeverolimustreatmentofmetastaticbreastcancer
AT danielsteinfort pneumocystisjiroveciipneumoniafollowingeverolimustreatmentofmetastaticbreastcancer
AT douglasjohnson pneumocystisjiroveciipneumoniafollowingeverolimustreatmentofmetastaticbreastcancer
_version_ 1724493731015426048

Similar Items